2.5. Safety Assessment
myalgia, fever, rhinorrhea, shortness of breath, impaired appetite, musculoskeletal and connective tissue disorders, lightheadedness, arthralgia, hematomas, itching, fatigue, diarrhea, cough, nasal congestion, hypersensitivity, nausea, vomiting, swelling, disorders of the respiratory system, throat, pain, headache
HEMATOMAS, NERVOUS SYSTEM DISORDERS, MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER, GASTROINTESTINAL TRACT DISORDERS, INDURATIONS, HYPERSENSITIVITY
AEs were monitored until Day 42–45 after the 1st vaccination (Day 28–31 after the last vaccination) for the 18–60 age cohort and until Day 63 (21 days after 3rd vaccination) for the 60+ age cohort. The solicited local AEs were pain, indurations, hematomas, swelling, itching and hypersensitivity at the injection site, and solicited systemic AEs were fever, fatigue or malaise, nervous system disorders (headache, lightheadedness), musculoskeletal and connective tissue disorders (arthralgia, myalgia), disorders of the respiratory system and mediastinal organs (pain/sore throat, nasal congestion, rhinorrhea, cough, shortness of breath), gastrointestinal tract disorders (nausea, vomiting, diarrhea, impaired appetite). All unsolicited AEs were reported by participants throughout the study.AEs were graded as mild, moderate or severe according to the severity scoring chart (